CL King Initiates Coverage On Integra Lifesciences with Buy Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
CL King analyst Kristen Stewart has initiated coverage on Integra Lifesciences (NASDAQ:IART) with a Buy rating and set a price target of $50.

November 14, 2023 | 3:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Integra Lifesciences received a Buy rating from CL King analyst Kristen Stewart with a price target of $50.
Analyst ratings, especially initiations of coverage with a Buy rating, can have a positive impact on a stock's price in the short term. The announcement of a price target above the current market price suggests a bullish outlook, which can lead to increased investor interest and potentially drive the stock price up.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100